新医学2023，Vol.54Issue(12)：879-883,5.DOI:10.3969/j.issn.0253-9802.2023.12.007
吡嗪酰胺耐药的耐多药结核分枝杆菌pncA基因表达分析
Analysis of pncA gene expression in pyrazinamide-resistant and multidrug-resistant Mycobacterium tuberculosis
摘要
Abstract
Objective To compare the expression levels of pncA gene in pyrazinamide(PZA)-resistant and multidrug-resistant Mycobacterium tuberculosis before and after PZA drug stimulation,and to explore the relationship between PZA-resistant Mycobacterium tuberculosis and pncA gene expression.Methods PZA-resistant and multidrug-resistant Mycobacterium tuberculosis was cultured,and the minimal inhibitory concentration(MIC)of rifampicin and PZA was detected.The strains were cultured in medium containing 0 and 50 μg/mL PZA,and the expression level of pncA was detected by real-time fluorescence quantitative PCR.Results The MIC of PZA of 21 strains of Mycobacterium tuberculosis was≥1 600 μg/mL,400-800 μg/mL for 12 strains,and 100-200 μg/mL in 5 strains,and their corresponding PZA resistance levels were defined as high,medium and low,respectively.The median MIC of rifampicin was 128,128 and 64μg/mL,respectively.Chi-square test showed that there was no significant difference between any two groups(all P>0.05).According to the relative quantitative 2-ΔΔCt method,the expression levels of pncA in the high,medium and low levels of PZA drug-resistant Mycobacterium tuberculosis was 0.904(0.202,2.653),1.157(0.658,1.511)and 1.147(0.372,1.347),and 1.544(0.611,3.191),0.846(0.421,1.237)and 0.726(0.225,3.017)in the 50 μg/mL treatment group,respectively.There was no significant difference in pncA gene expression between the control and PZA drug-containing culture groups(P>0.05).Conclusion No significant changes are observed in the expression levels of pncA in multidrug-resistant and PZA-resistant Mycobacterium tuberculosis before and after PZA drug stimulation.关键词
结核分枝杆菌/耐药/吡嗪酰胺/利福平/pncAKey words
Mycobacterium tuberculosis/Drug resistance/Pyrazinamide/Rifampicin/pncA引用本文复制引用
王楠,杨瑜,邓丽,吴玲,刘志辉,孟繁荣..吡嗪酰胺耐药的耐多药结核分枝杆菌pncA基因表达分析[J].新医学,2023,54(12):879-883,5.基金项目
广东省医学科学技术研究基金项目(A2023284) （A2023284）
广州市科技计划项目(202201010697) （202201010697）
广州市卫生健康科技项目(20241A011049) （20241A011049）
广州市结核病研究重点实验室(2023A03J0539) （2023A03J0539）
